Patents Assigned to Cytoskeleton Inc.
-
Patent number: 10690573Abstract: The present disclosure provides methods for reducing the viscosity of a cell lysate or tissue lysate by: contacting the cell lysate or tissue lysate with a compressible and open-cell foam filter having a pore size from about 0.65 mm to about 1.22 mm, compressing the filter to recover the lysate absorbed in the filter, and collecting the filtered lysate; and also provides kits therefor.Type: GrantFiled: May 25, 2017Date of Patent: June 23, 2020Assignee: Cytoskeleton, Inc.Inventors: Kim Middleton, Soonjin Hong, Wai K. Law, Henrick Horita
-
Patent number: 10288636Abstract: The present disclosure provides devices which deliver fluids from several reservoirs to a reaction vessel and eventually to a waste chamber in a predetermined schedule. The device provides improved simplicity while improving operational robustness and flexibility.Type: GrantFiled: February 8, 2017Date of Patent: May 14, 2019Assignee: Cytoskeleton, Inc.Inventors: Ashley Middleton-Davis, Kim Middleton-Davis
-
Patent number: 9599629Abstract: The present disclosure provides devices which deliver fluids from several reservoirs to a reaction vessel and eventually to a waste chamber in a predetermined schedule. The device provides improved simplicity while improving operational robustness and flexibility.Type: GrantFiled: November 14, 2014Date of Patent: March 21, 2017Assignee: Cytoskeleton, Inc.Inventors: Ashley Middleton-Davis, Kim Middleton-Davis
-
Publication number: 20100240551Abstract: The present invention provides methods of detecting activated Rho GTPase proteins by contacting a solid support with a sample comprising an activated Rho GTPase protein. The solid support is linked to an activated Rho GTPase binding peptide. The activated Rho GTPase protein remains associated with the solid support during the detection.Type: ApplicationFiled: June 2, 2010Publication date: September 23, 2010Applicant: CYTOSKELETON, INC.Inventors: Li Cheng, Ashley Davis, Kim Middleton
-
Patent number: 7763418Abstract: The present invention provides methods of detecting activated Rho GTPase proteins by contacting a solid support with a sample comprising an activated Rho GTPase protein. The solid support is linked to an activated Rho GTPase binding peptide. The activated Rho GTPase protein remains associated with the solid support during the detection.Type: GrantFiled: July 3, 2006Date of Patent: July 27, 2010Assignee: Cytoskeleton, Inc.Inventors: Li Cheng, Ashley Davis, Kim Middleton
-
Patent number: 7282571Abstract: In basic research and drug discovery there is a need to provide protein reagents with high activity. In particular proteins that are used in assays must have a good shelf life and a consistent activity. As a system of measuring actin polymerization, pyrene labeled actin was developed in 1983 by Kouyama and Mihashi. However, prior to this disclosure, pyrene actin has been impossible to store for longer than one month because the activity would be lost due to protein denaturation and frozen pyrene actin immediately lost activity. This disclosure relates a method for stabilizing pyrene labeled actin for extended storage times and an optimal storage buffer thus creating a reproducible source of pyrene actin for various assays. Using the processes described herein, pyrene actin has been stored for greater than 3 years at 4° C. which makes it a viable product for retail.Type: GrantFiled: February 3, 2004Date of Patent: October 16, 2007Assignee: Cytoskeleton Inc.Inventors: Ashley Stuart Davis, Kim Maria Middleton
-
Patent number: 7259278Abstract: It is presently accepted that the mechanism of action for all anti-tumor tubulin ligands involves the perturbation of microtubule dynamics during the G2/M phase of cell division and subsequent entry into apoptosis (1). In this invention, we report a novel tubulin ligands which have a unique mechanism of action. These compounds, halogenated derivatives of acetamido benzoyl ethyl ester (HAABE), arrest cancer cells in S-phase and cause cell death by a combination of apoptosis (DNA ladder) and necrosis (DNA degradation) type mechanisms. Normal cells are not affected at the same concentrations of compound. The ligands bind covalently to tubulin in vitro and in vivo and shows potent cancericidal activity in tissue culture assays and in animal tumor models. These compounds target early S-phase at the G1/S transition rather than the G2/M phase and mitotic arrest.Type: GrantFiled: November 29, 2000Date of Patent: August 21, 2007Assignee: Cytoskeleton Inc.Inventors: Ashley Stuart Davis, Kim Maria Middleton, Jain Dong Jiang, J. George Bekesi
-
Patent number: D806262Type: GrantFiled: June 12, 2015Date of Patent: December 26, 2017Assignee: Cytoskeleton, Inc.Inventors: Ashley Stuart Middleton-Davis, Kim Maria Middleton-Davis